Supplementary Material for: Functional and Patient-reported Outcomes in the Atorvastatin v

Supplementary material from the Atorvastatin Treatment of Cavernous Angioma Symptomatic Hemorrhage–Exploratory Proof-of-Concept (AT-CASH-EPOC) trial. The data includes functional and patient-reported outcome measures for 64 patients with cerebral cavernous malformations, collected at baseline, 1 year, and 2 years. The dataset was published by figshare admin karger on April 22, 2026, under a CC-BY-4.0 license.

Use Cases

• Analyzing longitudinal changes in functional status based on modified Rankin Scale (mRS) and NIH Stroke Scale (NIHSS) scores.
• Comparing patient-reported quality of life metrics based on EQ-5D-3L and visual-analogue scale data between treatment and placebo groups.
• Investigating correlations between patient-reported outcomes from PROMIS-29 domains and prospective symptomatic hemorrhage events.
• Assessing the specificity of functional decline for identifying occult bleeding as measured by quantitative susceptibility mapping (QSM).

Strengths

• Data originates from a prospective, double-blinded clinical trial (AT-CASH-EPOC), suggesting a controlled collection methodology.
• Includes longitudinal outcome data collected at three time points (baseline, 1 year, 2 years) for 64 patients.
• Outcomes are measured using standardized clinical scales (mRS, NIHSS) and validated patient-reported instruments (EQ-5D-3L, PROMIS-29).

Limitations

• The dataset is small (338.9 KB), and the description notes the small number of patients limits generalizability of findings.
• Column-level documentation is absent; field semantics must be inferred after download from the supplementary DOCX and PDF files.
• Row count is unknown, which may limit suitability assessment for certain analytical tasks.

Provenance

Source

figshare admin karger

Collection Method

Collected as part of the prospective, double-blinded AT-CASH-EPOC clinical trial where patients were randomized to atorvastatin or placebo.

Time Range

Data collection occurred at baseline, 1 year, and 2 years follow-up; specific years of the trial are not stated.

Freshness

Last updated 2026-04-22 07:55:10; freshness should be verified.